新闻发布

19.11.2018 | Nanion Technologies is pleased to welcome Dr. Ronald Knox to the team

LIVINGSTON, N.Y. USA, 19. November 2018: Nanion is pleased to announce the recent hire of Dr. Ronald Knox as Account Executive, who brings 18+ years of experience in drug discovery, target validation and translational research in neuroscience, cardiovascular and immunotherapies.

Within his new role, he will help drive business development and support for the CardioExcyte 96 and Syncropatch 384/768PE systems. Dr. Knox will leverage his Biopharma and academic networks to better understand the evolving landscape of CV ion channel safety pharmacology to help strengthen Nanion’s strategic support and commitment to the implementation of technology platforms that are comprehensively aligned with the global “Comprehensive In Vitro Proarrhythmia Assay” (CiPA) initiative.

Read the full press release here.

返回总览

 

New Genedata Screener®APC Functionality and Integration with Nanion SyncroPatch 384PE at SLAS2017

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.